These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis. Reynaud-Gaubert M; Viard L; Girault D; Bertault-Perez P; Guignard M; Metras D; Fuentes P Transplant Proc; 1997 Aug; 29(5):2450-3. PubMed ID: 9270807 [No Abstract] [Full Text] [Related]
3. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Friman S; Bäckman L Clin Pharmacokinet; 1996 Mar; 30(3):181-93. PubMed ID: 8882300 [TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Tan KK; Trull AK; Uttridge JA; Wallwork J Eur J Clin Pharmacol; 1995; 48(3-4):285-9. PubMed ID: 7589056 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. Kesten S; Scavuzzo M; Chaparro C; Szalai JP Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659 [TBL] [Abstract][Full Text] [Related]
6. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis. Girault D; Haloun A; Viard L; Bellon G; Gottrand F; Guillemain R; Lenoir G; Ladurie FL; Plouvier E; Storni V Transplant Proc; 1995 Aug; 27(4):2488-90. PubMed ID: 7652899 [No Abstract] [Full Text] [Related]
7. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110 [TBL] [Abstract][Full Text] [Related]
8. Cyclosporin new oral formulation for early oral immunosuppressive therapy in liver transplant recipients. Winkler M; Haller GW; Oldhafer K; Bechstein WO; Maibücher A; Färber L; Ringe B; Neuhaus P; Pichlmayr R Transplant Proc; 1997; 29(1-2):544-6. PubMed ID: 9123122 [No Abstract] [Full Text] [Related]
9. Comparison of two microemulsion of cyclosporine A in healthy volunteers. Tanasescu C; Serbanescu A; Spadaro A; Jen LH; Oliani C Eur Rev Med Pharmacol Sci; 1999; 3(1):5-9. PubMed ID: 10710823 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Cooney GF; Lum BL; Meligeni JA; Dunn SP Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222 [No Abstract] [Full Text] [Related]
12. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Coukell AJ; Plosker GL Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420 [TBL] [Abstract][Full Text] [Related]
13. [What significance has the C(2) value in the treatment with cyclosporin A?]. Pham VV; Stichtenoth DO; Frölich JC Dtsch Med Wochenschr; 2004 Mar; 129(13):706. PubMed ID: 15026970 [No Abstract] [Full Text] [Related]
14. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Schädeli F; Marti HP; Frey FJ; Uehlinger DE Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]